Gracell Biotechnologies
Signal active
Organization
Contact Information
Overview
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.
About
Industries
Biotechnology, Health Care, Medical
Founded
2017
Employees
251-500
Headquarters locations
Asia
Social
N/A
Profile Resume
Gracell Biotechnologies headquartered in Asia, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $13.7B in funding across 48 round(s). With a team of 251-500 employees, Gracell Biotechnologies is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Gracell Biotechnologies, raised $100.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
9
Lead Investors
0
Total Funding Amount
$285.0M
Details
3
Gracell Biotechnologies has raised a total of $285.0M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2019 | Early Stage Venture | 85.0M | ||
| 2018 | Early Stage Venture | |||
| 2020 | Late Stage Venture | 100.0M |
Investors
Gracell Biotechnologies is funded by 23 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| TCG Crossover | - | FUNDING ROUND - TCG Crossover | 100.0M |
| Logos Capital | - | FUNDING ROUND - Logos Capital | 100.0M |
| Gracell Biotechnologies | - | FUNDING ROUND - Gracell Biotechnologies | 100.0M |
| Adage Capital Management | - | FUNDING ROUND - Adage Capital Management | 100.0M |
Recent Activity
There is no recent news or activity for this profile.